M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Phase 1

Recruiting

Conditions: Metastatic Malignancy

Interventions: Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2022-05-27

Last Posted Date: 2025-04-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05394337

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Breast Cancer
Hepatocellular Carcinoma

Interventions: Drug: Piflufolastat F18

First Posted Date: 2022-05-27

Last Posted Date: 2025-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT05394259

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Rice Technologies for Cervical Cancer Screening and Diagnosis

Not Applicable

Recruiting

Conditions: Cervical Cancer

Interventions: Device: Multimodal optical imaging

First Posted Date: 2022-05-12

Last Posted Date: 2025-01-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 678

Registration Number: NCT05372484

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇲🇿
Mavalane Hospital and Health Center, Maputo, Mozambique
🇲🇿
José Macamo General Hospital and Health Center, Maputo, Mozambique

and more 1 locations

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

Phase 2

Recruiting

Conditions: HPV
Oropharyngeal Cancer

Interventions: Drug: Balstilimab

First Posted Date: 2022-05-06

Last Posted Date: 2025-05-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05363709

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Phase 2

Recruiting

Conditions: Myelodysplastic Syndromes
Myeloproliferative Chronic Myelomonocytic Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2022-05-06

Last Posted Date: 2025-05-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05365035

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: ASTX727
Drug: SNDX-5613
Drug: Venetoclax

First Posted Date: 2022-05-04

Last Posted Date: 2025-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT05360160

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB)

Not Applicable

Recruiting

Conditions: Hepatic
Liver Ablation

Interventions: Procedure: Liver ablation

First Posted Date: 2022-05-04

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT05361551

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Phase 2

Recruiting

Conditions: Mycosis Fungoides

Interventions: Drug: Brentuximab vedotin

First Posted Date: 2022-05-03

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05357794

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique

Not Applicable

Recruiting

Conditions: Cervical Cancer

Interventions: Behavioral: HPV testing of women for cervical cancer screening

First Posted Date: 2022-05-03

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14600

Registration Number: NCT05359016

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Phase 2

Recruiting

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Azacytidine
Drug: Pembrolizumab

First Posted Date: 2022-05-02

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05355051

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy